September 4, 2014 — Based on its recent analysis of the breast imaging solutions market, Frost & Sullivan recognized Volpara Solutions with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership.
Over the past few years, Volpara has steadily introduced several new solutions and expanded its global reach to cover the United States, Europe, Asia and Australia. Volpara’s suite of quantitative solutions includes VolparaDose, VolparaDensity, VolparaAnalytics and VolparaResearch. The Density and Dose solutions are patient-specific, while the Analytics and Research solutions are clinic-wide monitoring tools.
“Frost & Sullivan lauds Volpara Solutions for continuous leadership in technology innovation, thoughtfulness in identifying the unmet need for dose tracking in breast imaging and a clear vision for what analytics can achieve in the early detection and treatment of breast cancer,” said Siddharth Sadha, research director, Advanced Medical Technologies Group, Frost & Sullivan.
“Furthermore, all of the applications are built to serve across both full-field digital mammography (FFDM) and digital tomosynthesis systems, and with multi-vendor compatibility and reproducible data. This is of high relevance in the industry, as tomosynthesis is quickly gaining currency, with 30 percent of the members of the Society of Breast Imaging in the U.S. already using it,” he said.
While several market participants offer breast density measurement tools, Frost & Sullivan confirmed Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging. It is necessary to measure volumetric breast density to control the dose, and Volpara Solutions emerged as a pioneer in leveraging the mega-trend of dose reduction by acknowledging patient-specific dose tracking and reporting as a white-space opportunity.
“We are very proud to be recognized for the innovative solutions we have brought to the breast imaging market and for our vision and commitment to address unmet needs in the detection, prevention and treatment of breast cancer,” said Ralph Highnam, Ph.D., Volpara Solutions CEO and chief scientist. “By allowing researchers across the globe to compare data to detect geographical, racial and age-related trends, we hope to take breast cancer research to the next level, which could lead to the development of predictive analytical models that will revolutionize early detection of breast cancer and save lives.”
For more information: www.frost.com
April 29, 2025 
